How do you counsel patients on safety and toxicity of delgocitinib?

Are there patients in whom you would not offer this due to safety concerns? How do you explain to patients that topical JAK inhibitors carry a different risk profile than systemic JAK inhibitors?

Community PollStarted

Are there patients in whom you would avoid using topical delgocitinib for CHE?

30 physicians have voted

Join Mednetto vote and see how they answered.

2 Answers

Mednet MemberInvited Expert

Dermatology · Case Western Reserve University

Answered on

I request all eligible patients to complete the vaccines for herpes zoster prior to starting.

Delgocitinib has been reported to cause neutropenia, suggesting there is systemic absorption, so I do not recommend it for patients with a history of VTE.

I rarely see highly immunosuppressed patients with ...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert

Dermatology · Dermatologists of Central States

Answered on

I can't think of any situation, except maybe an active ongoing skin infection, in which I'd be hesitant to offer Anzupgo.

I do bring up that they are going to get information from the pharmacy that mentions some scary-sounding things that may be a risk with related medications taken as a pill, but t...

Join for free or sign in to see the full answer